Meeting
2016 ASCO Annual Meeting
Phase I dose-escalation trial of Sym004, a mixture of two anti-EGFR antibodies, in Japanese patients with advanced solid tumors.
Authors
Ken Kato
Gastrointestinal Medical Oncology Division, National Cancer Center Hospital, Tokyo, Japan
Ken Kato , Takashi Kojima , Kentaro Yamazaki , Kei Muro , Hiroki Hara , Keisho Chin , Thomas Goddemeier , Morihiro Watanabe , Toshihiko Doi
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Clinical Pharmacology and Experimental Therapeutics
Track
Developmental Therapeutics and Translational Research
Sub Track
Antibodies
Clinical Trial Registration Number
NCT01955473
Citation
J Clin Oncol 34, 2016 (suppl; abstr 2522)
DOI
10.1200/JCO.2016.34.15_suppl.2522
Abstract #
2522
Poster Bd #
222
Abstract Disclosures
Similar Posters
Poster
2011 ASCO Annual Meeting
Phase I trial of the first-in-class EGFR antibody mixture, Sym004, in patients with advanced solid tumors.
First Author: R. Dienstmann
Poster
2023 ASCO Annual Meeting
Nipavect: Phase II study of niraparib and panitumumab in advanced RAS WT colorectal cancer.
First Author: Olatunji B. Alese
Poster
2022 ASCO Annual Meeting
The combination of CD16A/EGFR innate cell engager, AFM24, with SNK01 autologous natural killer cells in patients with advanced solid tumors.
First Author: Anthony B. El-Khoueiry
Poster
2019 ASCO Annual Meeting
A phase I study evaluating COM701 in patients with advanced solid tumors.
First Author: Drew W. Rasco